Abstract:Background: There is a genetic component to the QT-interval. This study investigated whether a polygenic risk score for QTc (PRSQTc) could predict ∆QTc and short-term mortality in first-time users of QT-prolonging medications (QTPM) with a known risk of Torsade de Pointes. Methods: First-time users of psychoactive QTPM in the Copenhagen Hospital Biobank and the Danish Blood Donor Study from 2009-2021 were included. ∆QTc was calculated and all-cause 30-day mortality following initiation of treatment was explored. All models were adjusted for conventional QT-prolonging risk factors, and models investigating death were additionally adjusted for potential comorbidity confounders. Results: The PRSQTc could predict ∆QTc (2.88 milliseconds (ms) for every increase of standard deviation in PRSQTc (P <0.001)) following treatment initiation. Individuals in the top ≥80 % of PRSQTc had a higher risk of ∆QTc of ≥60 ms compared to individuals in <80 % PRSQTc (OR = 4.88 P = 0.019). Furthermore, the study has also shown that the shorter QTc before initiation of QTPM, the higher the risk of greater ∆QTc. A high PRSQTc could also predict short-term mortality following treatment initiation: Individuals in the top PRSQTc ≥90 % had an odds ratio of 1.84 (P-value = 0.002) for short-term mortality compared to individuals with PRSQTc <90 %. Individuals in the top PRSQTc ≥99 % had an odds ratio of 4.95 (P-value = 0.009) for short-term mortality compared to individuals in the <99 % PRSQTc It could be replicated that PRSQTc ≥90 % was a predictor of short-term mortality with OR 1.52 (P-value = 0.002) compared to PRSQTc <90 % in a bigger cohort (N=15.249). Conclusion: PRSQTc seems to be predictive of ∆QTc following initiation of treatment. PRSQTc proves to be a sufficient predictor of 30-day mortality after initiation of QT-prolonging psychoactive drugs with a known risk of Torsade de Pointes. If used in a clinical setting, PRSQT may help prevent sudden cardiac deaths associated with QTPM.

Polygenic risk score for drug-induced long QT syndrome: independent validation in a real-world patient cohort

A polygenic risk score for the QT interval is an independent predictor of drug-induced QT prolongation

Genetic risk factors for drug-induced long QT syndrome: findings from a large real-world case-control study

Polygenic Risk Score predicts QTc-prolongation and Short-Term Mortality in Patients using QT-prolonging Psychoactive Medications

Risk for Life-Threatening Cardiac Events in Patients with Genotype-Confirmed Long-Qt Syndrome and Normal-Range Corrected QT Intervals.

Risk of syncope in family members who are genotype-negative for a family-associated long-QT syndrome mutation.

Prediction of antipsychotics efficacy based on a polygenic risk score: a real-world cohort study

ATAD3B and SKIL polymorphisms associated with antipsychotic-induced QTc interval change in patients with schizophrenia: a genome-wide association study

Monogenic and Polygenic Contributions to QTc Prolongation in the Population

Impacts of gene variants on drug effects-the foundation of genotype-guided pharmacologic therapy for long QT syndrome and short QT syndrome

Assessing the Risk of QT Prolongation in a Psychiatric Inpatient Cohort: A Retrospective Cross-Sectional Study

Long QT syndrome in patients over 40 years of age: increased risk for LQTS-related cardiac events in patients with coronary disease.

Polygenic liability for antipsychotic dosage and polypharmacy - a real-world registry and biobank study

Prognostic Implications of Mutation-Specific QTc Standard Deviation in Congenital Long QT Syndrome.

Added value of patient‐ and drug‐related factors to stratify drug‐drug interaction alerts for risk of QT prolongation: Development and validation of a risk prediction model

Pharmacogenomics polygenic risk score: Ready or not for prime time?

Risk Factors for Recurrent Syncope and Subsequent Fatal or Near-Fatal Events in Children and Adolescents with Long Qt Syndrome

Bioinformatic Analysis of Key Genes in Cardiotoxic Compound Induced Long QT Interval

Polygenic risk scores for the prediction of cardiometabolic disease

QTNet: Predicting Drug-Induced QT Prolongation With Artificial Intelligence-Enabled Electrocardiograms

Machine learning in drug development: Characterizing the effect of 30 drugs on the QT interval using Gaussian process regression, sensitivity analysis, and uncertainty quantification